Thus, our work identifies the GluN2A subunit as the central mediator of NMDAR-associated nervous system pathology in SLE, supporting the use of GluN2A-specific negative allosteric modulators to treat SLE patients with brain dysfunction. Here, GRIN2A is linked to systemic lupus erythematosus.